Loading...

CHANGING THE STATUS QUO

Apellis unlocks the power of the complement pathway to develop new therapies for patients with immune mediated diseases.

APL-2 and C3 Inhibition



We believe that our lead product candidate, APL-2, has the potential to be a first-in-class treatment targeting C3 that may address the limitations of existing treatment options or provide a treatment option where there currently is none. APL-2 has already shown activity that we believe is clinically meaningful in clinical trials for two distinct medical conditions—geographic atrophy in age-related macular degeneration (GA) and paroxysmal nocturnal hemoglobinuria (PNH). We plan to conduct additional clinical trials in GA, PNH, autoimmune hemolytic anemia (AIHA) and complement-dependent nephropathies.
Apellis logo
© Apellis Pharmaceuticals 2018. | Privacy Policy